Ispire Technology Inc. — Form 10-Q Summary
Reporting period: Three and nine months ended March 31, 2024, filed May 14, 2024. This is fiscal 2024’s third quarter, notwithstanding the request metadata’s “2023 Q3.” The 2023 comparative statements were restated. The company develops, markets and distributes tobacco and cannabis vaping products and reports one operating segment.
Financial performance
| Metric | Three months ended March 31 | Nine months ended March 31 |
|---|---|---|
| Revenue | 2024: $30.0 million; 2023: $24.1 million | 2024: $114.6 million; 2023: $83.0 million |
| Gross profit / margin | 2024: $6.1 million / 20.4%; 2023: $4.5 million / 18.7% | 2024: $19.2 million / 16.8%; 2023: $14.3 million / 17.2% |
| Operating expenses | 2024: $11.8 million; 2023: $7.2 million | 2024: $29.8 million; 2023: $17.9 million |
| Operating loss | 2024: $5.7 million; 2023: $2.7 million | 2024: $10.5 million; 2023: $3.6 million |
| Net loss / diluted loss per share | 2024: $5.9 million / $0.11; 2023: $2.3 million / $0.05 | 2024: $11.3 million / $0.21; 2023: $4.5 million / $0.09 |
| Operating cash flow | Nine-month 2024: use of $16.9 million; 2023: provided $1.6 million |
- Nine-month revenue grew 38.1%; cannabis vaping sales increased to $48.8 million from $23.4 million, while tobacco vaping sales rose to $65.7 million from $59.6 million.
- Quarterly revenue grew 24.4%. Quarterly cannabis sales rose to $11.9 million from $7.6 million. Management attributed improved quarterly cannabis margins to more selective acceptance of higher-margin orders; nine-month cannabis margins were lower amid pricing negotiated by larger customers.
- Nine-month operating expenses increased 66.5%, including $4.7 million of stock-based compensation, higher credit-loss expense, added staffing and public-company professional fees.
Financial position and liquidity
- At March 31, 2024, cash was $39.5 million, current assets $98.7 million, current liabilities $69.7 million and working capital $28.9 million. Working capital was nearly unchanged from June 30, 2023; the current ratio was approximately 1.4.
- Accounts receivable, net, increased to $47.7 million from $24.5 million. The allowance for credit losses rose to $4.0 million from $1.5 million; nine-month credit-loss expense was $3.3 million.
- Operating cash outflow primarily reflected a $26.6 million increase in receivables and a $2.5 million increase in inventory. Cash decreased by $0.8 million over the nine months, after a $9.1 million short-term investment matured and the company raised $12.3 million gross in a share offering.
- Total liabilities were $72.5 million. The largest current obligation was $61.0 million payable to related-party supplier Shenzhen Yi Jia, with no fixed payment terms; the filing classifies it as current. Operating lease liabilities totaled $4.0 million. The filing reports no conventional borrowings on the balance sheet.
- Management said cash and working capital should cover needs for the next 12 months, but noted that adverse operations, unexpected capital spending or accelerated growth could require additional financing and potentially dilute shareholders.
Material changes, outlook and risks
- Restatement and controls: The filing restates 2023 interim information, including reclassification of shipping and handling costs and operating-lease cash flows. It also describes a correction that reduced a previously stated March 2023 intangible-asset balance of $74.3 million to zero and changed comparative net losses. Management concluded disclosure controls were ineffective, citing weaknesses in accounting for assets acquired from a controlling stockholder, evaluating inventory and credit-loss estimates, and written control policies. The company continued remediation efforts.
- Related parties and concentration: Shenzhen Yi Jia, 95% owned by the co-CEO, supplied 77% of purchases for the nine months and was owed $61.0 million at quarter-end. One customer represented 31% of nine-month revenue. These concentrations heighten supplier, customer, collection and governance risks.
- Regulation: Vaping rules vary by jurisdiction. The company sells only one tobacco vaping product line in the U.S. and has stopped marketing it there; a PMTA is pending for one ENDS product and the FDA could reject it. Cannabis products face differing state rules and remain subject to federal legal risk; the filing says cannabis vaping products cannot be sold in the EU or UK.
- Investments and commitments: The company invested $1 million in Berify and completed an additional $1 million investment on April 5, 2024. Also on April 5, it entered a joint venture for vapor-device age verification and related PMTA work, contributed $1 million and committed to additional contributions of up to $9 million. It issued Berify a warrant for 111,111 shares at $9 per share, expiring in 2029.
- Other items: A current employee sent a demand letter on April 12, 2024 alleging workplace issues; the company disputes the claims and says it will defend itself. The filing reports no forecasted revenue or earnings guidance. It also identifies cybersecurity exposure and uncertainty around regulatory changes as risks.
Most important facts for investors to verify
- Reconcile the restated comparative financial statements, including the intangible-asset correction and the differing operating-lease reclassification amounts described in the filing.
- Assess receivables aging, subsequent collections, customer concentration and the adequacy of the $4.0 million credit-loss allowance.
- Evaluate the terms, settlement timing and governance safeguards for the $61.0 million related-party payable and the company’s reliance on its related-party supplier.
- Track cash generation against the joint venture’s potential additional $9 million contribution and other investment and manufacturing commitments.
- Monitor remediation of the disclosed control weaknesses and subsequent developments concerning the FDA inquiry, PMTA review and employee demand.
- Verify the nine-month 2024 gross margin: the financial statements show 16.8%, while one MD&A passage states 16.6%.